title: Antinociceptive effect in mice of intraperitoneal N-methyl-D-aspartate receptor antagonists in the formalin test.
abstract: Although the antinociceptive effect of NMDA antagonists in the formalin test is well recognised, these compounds can induce adverse motor effects. The aim of this study was to identify the systemic doses of NMDA antagonists that induce analgesia without causing side effects. Male Swiss mice (30-40g) received a subcutaneous (sc) injection of 1.25% formalin (50 micro l) in the dorsal surface of the right hind-paw and, 15min before or after formalin, an ip injection of one of the following NMDA receptor antagonists: MK 801 (0.01, 0.025, and 0.05mg/kg), memantine (0.1, 0.5, and 1mg/kg), ketamine (0.125, 0.25, and 0.5mg/kg), dextromethorphan (5, 10, and 20mg/kg), and CGP 37849 (4, 6, and 8mg/kg). Pain-related behaviour (licking, lifting, favouring, shaking, and flinching of the treated paw) was recorded at 5-min intervals for 60min. The NMDA receptor antagonists significantly (p<0.01) and dose-dependently reduced, versus controls, nociceptive activity during the second phase of the formalin test (from the 20th to the 60thmin): at the highest doses, 97.6+/-0.1% with MK 801; 90.4+/-0.2% with memantine; 74.7+/-0.3% with ketamine; 92.8+/-0.4% with dextromethorphan; and 80.7+/-0.3% with CGP 37849, without affecting coordination. The rank order potency of antinociceptive activity of NMDA antagonists was: MK801>memantine>ketamine>dextromethorphan>CGP37849. The NMDA antagonists administered after formalin (during the analgesic interval) did not affect the late phase of the formalin test. In conclusion, systemic administration of NMDA receptor antagonists decreases the nociception observed during the late phase of the formalin test.
authors.affiliation: Department of Experimental Medicine, Section of Pharmacology 'L. Donatelli', Second University of Naples, via Costantinopoli 16, I-80138, Naples, Italy. liberato.berrino@unina2.it
authors.forename: Liberato
authors.initials: L
authors.lastname: Berrino
authors.forename: Patrizia
authors.initials: P
authors.lastname: Oliva
authors.forename: Francesco
authors.initials: F
authors.lastname: Massimo
authors.forename: Caterina
authors.initials: C
authors.lastname: Aurilio
authors.forename: Sabatino
authors.initials: S
authors.lastname: Maione
authors.forename: Antonio
authors.initials: A
authors.lastname: Grella
authors.forename: Francesco
authors.initials: F
authors.lastname: Rossi
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003915:Dextromethorphan / Q000008:administration & dosage*; D016291:Dizocilpine Maleate / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage*; D005557:Formaldehyde / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007649:Ketamine / Q000008:administration & dosage*; D008297:Male; D008559:Memantine / Q000008:administration & dosage*; D051379:Mice; D009619:Nociceptors / Q000187:drug effects*; D010146:Pain / Q000523:psychology
chemical_list: D018691:Excitatory Amino Acid Antagonists; D005557:Formaldehyde; D007649:Ketamine; D016291:Dizocilpine Maleate; D003915:Dextromethorphan; D008559:Memantine